Clinical Trial Update: Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on using the anticoagulant rNAPc2 to reduce major adverse cardiac events in patients with coronary artery disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• rNAPc2 (rNAPc2)

Snippet

Sponsor: ARCA Biopharma, Inc. | Conditions: Coronary Disease | Phase 2 | Status: COMPLETED